Lucentis | Beye

Compare Anti-VEGF

4 products »

Home > Ophthalmic Drugs > Anti-VEGF

1630

Lucentis

Genentech, Inc.

Lucentis (ranibizumab injection) is a a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).

TOP

Description

Related Products

Details

From Your Peers

Company

At-a-Glance

Mechanism of Action: Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Dosage:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD): 0.5 mg (0.05 mL) to be administered by intravitreal injection once a month (approximately 28 days).
- Macular Edema Following Retinal Vein Occlusion (RVO): 0.5 mg (0.05 mL) to be administered by intravitreal injection once a month (approximately 28 days).
- Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): 0.3 mg (0.05 mL) to be administered by intravitreal injection once a month (approximately 28 days).
- Myopic Choroidal Neovascularization (mCNV): 0.5 mg (0.05 mL) to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed.

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Ranibizumab

Application

Intravitreal

Status

Prescription

Strength

Not specified

From Your Peers

Vision Expo East 2018: Highlights

Vision Expo East 2018: Highlights

READ ARTICLE »

The DRCR.net Protocol T study in patients with DME and baseline visual acuity of 20/50 or worse demonstrated that patients receiving ranibizumab or aflibercept treatment showed improved outcomes compared with those receiving bevacizumab."

Innovations in Diabetic Eye Disease

S.K. Steven Houston III, MD

READ ARTICLE »

Show More

Company Information

Contact the company for additional information, availability, or pricing:

Genentech, Inc.

www.gene.com

1 DNA Way

South San Franciso, CA 94080

Compare Anti-VEGF »

4 products »

View All Anti-VEGF »

4 products »

Privacy | Terms & Conditions Ⓒ 2024 Beye, LLC. All rights reserved.

This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.